Lessons From the Other Side of Academic Publishing: My Experience as an ASCO Journals Editorial Fellow
By Mona Hassan, MDFor many oncology fellows, including me, the ultimate goal is to have an academic career combining research and clinical practice. At the beginning of fellowship, and as your early career takes off, you focus on doing as much research as you can and publishing as many papers as possible. Of course,...
Set Up Your Collaborative Team for Success: A Guideline for Advanced Practice Provider/Physician Team-Based Care in Oncology
By Tammy Triglianos, DNP, ANP-BC, AOCNP, Ethan Basch, MD, MSc, FASCO, and Matthew Milowsky, MD, FASCONot only are the number of advanced practice providers (APPs) practicing in oncology continuing to increase, but the role of APPs caring for patients with cancer continues to expand. APPs have significant roles in providing continuity of patient care...
Chemotherapy for prostate cancer is currently limited to metastatic disease, but results from the Radiation Therapy Oncology Group (RTOG) 0521 trial indicate its possible usefulness in some cases of aggressive, early-stage disease. "The trial suggests that docetaxel chemotherapy may be an option to be discussed with selected men with high-risk prostate cancer," conclude the investigators,...
SAN FRANCISCO — Retroperitoneal lymph node dissection (RPLND) could potentially be a first-line option for men with stage II A/B testicular seminoma in order to reduce long-term toxicity and secondary malignancies, suggest data from two new studies. Although RPLND is currently rarely used as first-line therapy in testicular seminoma, overall survival rates appear to be excellent,...
Originally published in "Discussions with Don S. Dizon" on The Oncologist. One of the most valuable jobs I held following fellowship was working as a full-time deputy editor at UpToDate. My “territory” was breast, gynecologic, and genitourinary oncology, and I helped launch cancer survivorship and palliative care. I learned to really and critically read the literature,...
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors (TKI). Consequently, cytokines treatment such as interferon-α and interleukin-2 (IL-2), which were the standard-of-care treatment until then, were quickly abandoned or restricted to very selected situations (like IL-2). Several...
ESMO/ASCO Global Curriculum Working Group Chair Christian Dittrich, MD, Professor of Medicine Head of 3rd Medical Department—Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria Members Emilio Alba Conejo, MD Director of UGCI Oncology Intercentros, Hospital Universitario Virgen de la Victoria y Regional de Malaga, Malaga, Spain Rossana Berardi, MD, Professor of Medical Oncology Head of Department of Medical Oncology, Università...
Time Management Tips
17.6 ° C